Abstract
Introduction: Severe eosinophilic asthma is increasingly recognised as a heterogeneous phenotype. Benralizumab has a unique ability to deplete blood and tissue eosinophils. Assessing clinical characteristics of patients who have a marked response to treatment (super-responders) can aid our understanding of severe asthma.
Methods: ANDHI was a double-blind, placebo-controlled, 6-month study of patients with severe uncontrolled asthma and blood eosinophil levels (EOS) ≥150/µL. Rates and clinical characteristics of super-responders to benralizumab were evaluated (Table).
Super-responder criteria*
Results: Super-response was achieved in 53% of benralizumab and 35% of placebo patients (OR=2.14; p<0.0001) (Figure) and 60% of benralizumab patients with EOS ≥300/µL. Benralizumab super-responders had higher EOS (≥450/µL; 54% vs 27%), OCS use (23% vs 17%), adult-onset asthma (79% vs 62%), nasal polyposis (40% vs 27%), and less Phadiatop positivity (49% vs 65%) compared with non-super-responders.
Conclusions: Certain clinical characteristics are associated with a dramatic response to benralizumab offering additional insights into the eosinophilic asthma phenotype.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3734.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
